Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease
28/10/2024 18:31
Oct 28 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN
PATENT
COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL
DISEASE
Source text: ID:nGNXbbw47D
Further company coverage: ABS.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease